Biosimilars Market Size, Share, and Growth Forecast 2026 - 2033

The global biosimilars market is expected to be valued at US$ 28.5 billion in 2026 and is projected to reach US$ 95.2 billion by 2033, growing at a CAGR of 18.8% between 2026 and 2033.

The market is primarily driven by the loss of exclusivity of blockbuster biologics, which opens large revenue pools to lower-cost alternatives. Patent expiries and loss of market exclusivity for adalimumab, ustekinumab, aflibercept, and denosumab, combined with evolving regulatory pathways from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are accelerating biosimilar development and launches. Payer pressure to contain biologic spending further strengthens uptake across hospital and retail settings.

Drivers - Patent Cliff of Blockbuster Biologics Unlocking Large Revenue Pools

The expiry of patents and loss of exclusivity for high-revenue biologics represent the most significant drivers of the biosimilars market. AbbVie's Humira generated over US$ 21 billion in global sales in 2022 before losing U.S. exclusivity in January 2023, after which multiple adalimumab biosimilars entered the U.S. market. Johnson & Johnson's Stelara, with global sales of nearly US$ 11 billion in 2023, faced multiple biosimilar launches in 2025, while Regeneron's Eylea and Amgen's Prolia/Xgeva have also faced biosimilar competition.

Key oncology antibodies such as Merck's Keytruda, which recorded about US$ 29.5 billion in sales in 2024, are expected to face biosimilar competition in the U.S. beginning in late 2028, subject to patent protections and litigation outcomes. This continuing pipeline of exclusivity losses provides biosimilar developers with a multi-year pipeline of launch opportunities and potential revenue growth.

Healthcare Cost Containment and Proven Savings for Payers

Rising biologic spending is pushing governments, insurers, and hospital systems to actively favor biosimilars. Biologics account for a disproportionate share of drug spending despite representing a small fraction of prescriptions. According to the Association for Accessible Medicines (AAM), biosimilars generated about US$ 12.4 billion in U.S. savings in 2023 alone and roughly US$ 36 billion cumulatively since 2015.

In Europe, national tendering systems and gain-sharing schemes, such as those operated by NHS England, have driven rapid switching to adalimumab and infliximab biosimilars. Pharmacy benefit managers such as CVS Caremark removed Humira from major formularies in 2024 in favor of selected biosimilar alternatives, demonstrating how payer decisions can rapidly shift market share and expand biosimilar adoption.

Restraints - High Development Costs and Complex Manufacturing Requirements

Developing a biosimilar typically requires US$ 100 to 300 million and takes six to nine years, significantly longer and costlier than the development of small-molecule generics. Production involves living cells, and even minor variations in cell culture conditions, pH, or temperature can alter glycosylation patterns and other product attributes, affecting product comparability, quality, and manufacturing consistency.

Manufacturing costs for recombinant proteins vary considerably by product, process, and production scale, making production capital-intensive. Additionally, stringent quality control, extensive analytical testing, and compliance with regulatory standards increase development timelines and costs.

High entry barriers limit smaller companies from entering the market and constrain competition, particularly in complex biologic categories. These manufacturing complexities, combined with long development timelines, contribute to limited market penetration in some regions despite strong demand, making cost and technical challenges persistent restraints on biosimilar growth.

Opportunities - Patent Expiries of GLP-1 Receptor Agonists Creating a New High-Volume Category

GLP-1 receptor agonists represent an emerging opportunity for developers of lower-cost alternatives. The International Diabetes Federation (IDF) estimates that about 589 million adults were living with diabetes in 2024, while the World Health Organization (WHO) reports that more than one billion people worldwide live with obesity. Semaglutide patent and exclusivity timelines vary by country, with key patent protections expected to expire in selected markets, including China, in 2026. However, patent expiry alone does not guarantee immediate market entry, as regulatory requirements, additional patent protections, and manufacturing considerations also influence commercialization.

Teva launched a generic version of liraglutide in the U.S. in 2024, and Biocon Biologics secured approval for liraglutide in the U.K. in 2024. Companies such as Dr. Reddy's, Lupin, and Sun Pharma are pursuing opportunities in the broader GLP-1 segment, positioning lower-cost GLP-1 therapies as a potential source of volume and revenue growth through 2033. The classification of these products as generics, biosimilars, or other follow-on therapies depends on the molecule and the regulatory framework of each market.

Regulatory Streamlining and Interchangeability Expanding Uptake

Regulatory reforms are reducing the clinical testing burden and improving the efficiency of biosimilar development, creating opportunities for established players and new entrants. In June 2024, the FDA issued draft guidance updating its recommendations for demonstrating interchangeability, reflecting evolving scientific approaches to switching studies. In October 2025, the FDA proposed reducing the need for comparative efficacy studies when robust analytical evidence supports biosimilarity. These measures reflect a broader shift toward analytical evidence and risk-based clinical requirements.

The Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K. and the EMA have also adopted scientific approaches that support streamlined biosimilar development while maintaining established standards for quality, safety, and efficacy. Interchangeable designation allows pharmacy-level substitution under applicable U.S. state laws, potentially accelerating adoption through retail pharmacies. These regulatory developments are expected to reduce development costs, improve development efficiency, and encourage a broader product pipeline, particularly for complex monoclonal antibodies and ophthalmology products.

Drug Class Insights

Monoclonal antibodies (mAbs) represent the leading drug class segment, accounting for 46% of the market share in 2026, driven by their high clinical value in oncology and autoimmune diseases. More than 80 biosimilar candidates targeting 38 reference biologics are reported to be in development, with many focusing on mAbs such as trastuzumab, rituximab, and bevacizumab. These reference biologics have historically generated billions of dollars in annual sales, with trastuzumab alone generating nearly US$ seven billion in global sales in 2013 before biosimilar competition expanded.

High demand for cost-effective alternatives in conditions such as breast cancer, rheumatoid arthritis, and inflammatory bowel disease drives adoption. Regulatory pathways in the U.S. and Europe have enabled multiple mAb biosimilars to gain approval, supporting broader access to these therapies. Additionally, established manufacturing capabilities and extensive clinical experience with reference products make mAbs attractive for biosimilar developers. Their high revenue potential and clinical significance position mAbs as the leading drug class in the biosimilars market.

Route of Administration Insights

Intravenous administration remains the leading segment, accounting for nearly 47% of the market share in 2026. Several high-value oncology and immunology biosimilars, including trastuzumab, bevacizumab, rituximab, infliximab, and eculizumab, are administered through intravenous infusions in hospitals and infusion centers. Their adoption is supported by established treatment protocols, hospital procurement practices, and growing acceptance of biosimilars as cost-effective alternatives to reference biologics. In the U.S., oncology biosimilars have achieved substantial uptake, with some trastuzumab and bevacizumab biosimilars gaining significant market shares following their launches.

Intravitreal administration is expected to register the fastest growth from 2026 to 2033, driven by biosimilars targeting retinal diseases, including age-related macular degeneration and diabetic macular edema. Products such as Amgen's Pavblu and Biocon's Yesafili are strengthening competition in the ophthalmology segment. Growing demand for affordable retinal treatments and increasing biosimilar availability are expected to support the expansion of this segment.

Distribution Channel Insights

Hospital pharmacies are expected to lead the biosimilars market, accounting for around 58% of the market share in 2026. Hospitals and affiliated infusion centers manage substantial volumes of oncology and immunology biosimilars, particularly intravenous formulations. Formulary decisions, centralized procurement, group purchasing organizations, and reimbursement arrangements influence product selection and purchasing volumes. In Europe, hospital-based tendering systems in countries such as Norway, Denmark, and the U.K. have supported biosimilar adoption through competitive pricing and procurement policies. These established purchasing structures are expected to strengthen the position of hospital pharmacies throughout the forecast period.

Online pharmacies are expected to record the fastest growth from 2026 to 2033, supported by increasing availability of self-administered therapies, digital prescription services, and home-delivery models. However, growth depends on product suitability, cold-chain logistics, prescribing practices, and reimbursement regulations. Platforms such as Mark Cuban Cost Plus Drug Company support price transparency and access to selected medicines, although online distribution remains more relevant to eligible outpatient therapies than to hospital-administered biosimilars.

North America Biosimilars Market Trends and Insights

North America is expected to lead the global biosimilars market, accounting for around 39% of the market share in 2026, supported by high biologics expenditure, established healthcare infrastructure, and increasing adoption of cost-effective alternatives to reference biologics.

Recent patent expiries and the loss of market exclusivity for major biologics, including adalimumab, ustekinumab, and denosumab, have expanded opportunities for biosimilar manufacturers. Growing competition among manufacturers, pharmacy benefit manager partnerships, and broader formulary inclusion are shaping market access strategies. In Canada, provincial switching policies are also encouraging transitions from originator biologics to biosimilars, supporting wider adoption across multiple therapeutic areas.

The U.S. dominates the North American biosimilars market, driven by FDA approvals, competitive pricing, and payer-led formulary changes. Interchangeable designations and evolving reimbursement practices are improving access to selected products. Biosimilars targeting oncology, immunology, and ophthalmology are strengthening competition, while upcoming patent expiries and the loss of exclusivity for established biologics are expected to create further opportunities. However, pricing pressure, complex reimbursement arrangements, and manufacturer contracting strategies continue to influence the pace of market penetration across the region.

U.S. Biosimilars Market Size

The U.S. accounts for around 88% of the North American biosimilars market in 2026, supported by high biologics expenditure, expanding product availability, and growing payer acceptance. The U.S. Food and Drug Administration (FDA) has approved more than 60 biosimilars since 2015, with the total increasing further by 2026.

Adalimumab biosimilar adoption gained momentum in 2024 following formulary changes by major pharmacy benefit managers. Increasing competition, interchangeable designations, and cost-containment initiatives are supporting market expansion. Upcoming patent expiries for oncology antibodies and other high-value biologics are expected to create further opportunities, while reimbursement complexities and pricing competition continue to influence adoption.

Europe Biosimilars Market Trends and Insights

Europe represents a mature market, supported by established regulatory frameworks, extensive clinical experience, and national healthcare cost-containment policies. Since the first biosimilar approval in 2006, adoption has expanded across oncology, immunology, endocrinology, and supportive care. Competitive tendering, physician prescribing guidance, and hospital procurement programs have contributed to wider use. Increasing availability of biosimilars for ustekinumab, denosumab, and aflibercept is expanding competition. Growing emphasis on healthcare savings and sustainable biologic expenditure is expected to support market development across European countries.

Germany, the U.K., and France are major markets, supported by established healthcare systems and national or regional biosimilar policies. Germany benefits from prescribing targets and statutory health insurance coverage, while the U.K. uses NHS procurement frameworks to encourage best-value biologic selection. France is strengthening adoption through reimbursement measures, hospital incentives, and expanded substitution policies for eligible products. Differences in prescribing practices, procurement arrangements, and reimbursement rules continue to influence adoption rates across individual countries and therapeutic categories.

Germany Biosimilars Market Size

Germany accounts for an estimated 24% of the European biosimilars market revenue, supported by high biologic consumption, comprehensive statutory health insurance coverage, and established biosimilar prescribing practices. Regional physician associations and the Federal Joint Committee (G-BA) influence prescribing through applicable regulations, guidance, and quota-based arrangements. These measures encourage the use of cost-effective biosimilars while maintaining treatment quality. Strong hospital procurement and competition among manufacturers further support adoption across oncology, immunology, and other specialty areas.

U.K. Biosimilars Market Size

The U.K. accounts for an estimated 15% of the European biosimilars market in 2026, supported by the National Health Service (NHS), centralized procurement, and established cost-saving initiatives. NHS England's commercial frameworks encourage the use of best-value biologic medicines, helping healthcare providers manage treatment expenditure. Biosimilars have gained substantial adoption in several therapeutic areas, including immunology and oncology. National guidance and procurement arrangements also support competition among manufacturers, improving opportunities for biosimilar uptake across hospitals and eligible outpatient treatment settings.

Asia Pacific Biosimilars Market Trends and Insights

Asia Pacific represents the fastest-growing regional market, driven by large patient populations, rising biologic demand, healthcare cost-containment initiatives, and expanding domestic manufacturing capabilities. China and India are important contributors, supported by local pharmaceutical companies and evolving regulatory frameworks. Government procurement initiatives and increasing access to lower-cost biologic treatments are strengthening adoption across oncology, immunology, and diabetes care. Growing investment in manufacturing capacity and research is expected to support regional competition and product availability.

China's expanding biosimilar industry and India's established biosimilar manufacturing base are important growth drivers. Japan also supports regional demand through healthcare policies encouraging biosimilar use and efforts to manage expenditure associated with an aging population. Improvements in regulatory capabilities, manufacturing infrastructure, and distribution networks are creating opportunities for domestic and international manufacturers. However, differences in reimbursement systems, clinical acceptance, pricing, and approval requirements continue to influence market development across individual Asia Pacific countries.

India Biosimilars Market Size

India is a rapidly growing market within Asia Pacific, supported by domestic manufacturers such as Biocon Biologics, Dr. Reddy's Laboratories, Intas Pharmaceuticals, and Zydus Lifesciences. The Central Drugs Standard Control Organisation (CDSCO) provides regulatory guidelines for similar biologics, supporting product development and approval. Increasing demand for affordable treatments across oncology, diabetes, and autoimmune diseases is creating growth opportunities.

The expiry of key semaglutide patent protection in India in 2026 is expected to accelerate competition from lower-cost alternatives, expand treatment options, and improve access to diabetes and obesity therapies. However, market development depends on regulatory approvals, product availability, pricing, and prescribing practices.

Japan Biosimilars Market Size

Japan is projected to hold a significant share of the Asia Pacific biosimilars market in 2026, supported by an aging population, high healthcare standards, and established demand for biologic medicines. The Ministry of Health, Labour and Welfare (MHLW) promotes biosimilar adoption through national targets and healthcare policies aimed at improving treatment affordability. Reimbursement incentives for eligible healthcare providers also encourage adoption. Increasing use of biologics in oncology, rheumatology, and other chronic diseases is creating opportunities for biosimilar manufacturers across the country.

The global biosimilars market is moderately consolidated, with leading players such as Sandoz, Amgen, Celltrion, Biocon Biologics, Samsung Bioepis, and Pfizer holding a substantial share of revenue. Market leaders differentiate through broad portfolios, in-house manufacturing scale, device innovations such as high-concentration and citrate-free formulations, and early-to-market launches. Strategic partnerships are common, such as Teva with Alvotech and Organon with Samsung Bioepis, combining development capability with commercial reach.

Emerging business models include private-label agreements with pharmacy benefit managers, direct-to-patient distribution, and contract development and manufacturing partnerships. Companies are increasingly investing in next-wave targets such as pembrolizumab, nivolumab, and semaglutide to secure future growth.

Key Industry Developments

• In Oct 2026, Kamada expanded its biosimilar portfolio in Israel by commercially launching two additional products, increasing its marketed biosimilar portfolio to four products and strengthening its presence in the Israeli biopharmaceutical market.
• In Oct 2026, Teva and Samsung Bioepis expanded their strategic partnership to develop and commercialize up to six biosimilar candidates, including products referencing Fasenra and Ilaris, targeting the US, European, and Canadian markets.
• In Jun 2026, the US FDA approved Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Roche/Genentech’s Lucentis. It became the first interchangeable Lucentis biosimilar approved in single-dose vial and prefilled syringe presentations, available in 0.3 mg and 0.5 mg strengths, expanding treatment options for patients with retinal diseases.
• In Mar 2026, Sandoz established a dedicated global biosimilar development, manufacturing, and supply unit, appointing Armin Metzger to lead the division from April 2026. The initiative aims to accelerate biosimilar growth, strengthen manufacturing capabilities, improve supply efficiency, and capitalize on upcoming biologic patent expiries worldwide.